ImmunityBio COVID-19 vaccine

The ImmunityBio COVID-19 vaccine, codenamed hAd5, is a non replicating viral vector[1] COVID-19 vaccine developed by the United States-based ImmunityBio.[2][1]

ImmunityBio
Vaccine description
TargetSARS-CoV-2
Vaccine typeViral vector
Clinical data
Trade nameshAd5

Manufacturing

The BioVac Institute, a state-backed South African vaccine company, plans to use a deal it won to manufacture coronavirus vaccines. The contract with American based ImmunityBio Inc is currently conducting phase 1 vaccine trials in South Africa[3]

ImmunityBio and BioVac plan to distribute the vaccines throughout South Africa and Africa.[4][5]

History

In April 2020, a product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine.[6]

On 1 June 2020, the product was selected for inclusion on the Operation Warp Speed subsidy list, in order to fund monkey trials.[7] The company "hope to receive approval from the Food and Drug Administration to begin an initial safety trial in humans in June 2020."[7]

Clinical trials

ImmunityBio Inc is currently conducting phase 1 vaccine trials in The United States and South Africa.[3][8][9]

References
  1. "ImmunityBio Inc: hAd5-Covid-19 – COVID19 Vaccine Tracker". covid19.trackvaccines.org. Retrieved 23 March 2021.
  2. "SA's Biovac to team up with US based ImmunityBio in making its vaccine". BusinessInsider. Retrieved 23 March 2021.
  3. "Covid-19 to Serve as Platform for South African Vaccine Industry". Bloomberg.com. 19 March 2021. Retrieved 20 March 2021.
  4. Fisher S. "Nzimande excited about vaccine partnership between Biovac & ImmunityBio". ewn.co.za. Retrieved 20 March 2021.
  5. Sguazzin A. "SA's BioVac to use deal with US-based ImmunityBio to boost local vaccine creation, CEO says". Fin24. Retrieved 20 March 2021.
  6. Cross R (12 May 2020). "Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past?". Chemical & Engineering News. 98 (19).
  7. Cohen J (1 June 2020). "Operation Warp Speed selects billionaire scientist's COVID-19 vaccine for monkey tests". American Association for the Advancement of Science. Science (magazine).
  8. "ImmunityBio Announces Phase I Trial of COVID-19 Vaccine Candidate in South Africa as New Variants of SARS-CoV-2 Spread". www.businesswire.com. 19 January 2021. Retrieved 23 March 2021.
  9. Sguazzin A. "SA's BioVac to use deal with US-based ImmunityBio to boost local vaccine creation, CEO says". Fin24. Retrieved 23 March 2021.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.